Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer

Tomohiro Shibata; Eriko Tokunaga; Satoshi Hattori; Kosuke Watari; Yuichi Murakami; Nami Yamashita; Eiji Oki; Junji Itou; Masakazu Toi; Yoshihiko Maehara; Michihiko Kuwano; Mayumi Ono

doi:10.18632/oncotarget.26469

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer

Tomohiro Shibata _, Eriko Tokunaga, Satoshi Hattori, Kosuke Watari, Yuichi Murakami, Nami Yamashita, Eiji Oki, Junji Itou, Masakazu Toi, Yoshihiko Maehara, Michihiko Kuwano and Mayumi Ono

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:37216-37228. https://doi.org/10.18632/oncotarget.26469

Metrics: PDF 1640 views | HTML 1927 views | ?

Abstract

Tomohiro Shibata1, Eriko Tokunaga2, Satoshi Hattori3, Kosuke Watari1, Yuichi Murakami1,4, Nami Yamashita5, Eiji Oki5, Junji Itou6, Masakazu Toi6, Yoshihiko Maehara7, Michihiko Kuwano4 and Mayumi Ono1

1Department of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan

2National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

3Department of Integrated Medicine, Biomedical Statistics, Osaka University Graduate School of Medicine, Osaka, Japan

4Cancer Translational Research Center, St. Mary's Institute of Health Sciences, Kurume, Japan

5Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

6Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

7Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan

Correspondence to:

Mayumi Ono, email: [email protected]

Keywords: YBX1; ER; breast cancer; predictive biomarker; antiestrogen resistance

Received: November 08, 2018 Accepted: December 05, 2018 Published: December 14, 2018

ABSTRACT

The enhanced expression of the Y-box binding protein YBX1 is consistently correlated with poor outcomes or reduced survival of breast cancer patients. However, the mechanism underlying the association between increased YBX1 expression and poor outcomes has yet to be revealed. We searched a database for the top 500 genes that are positively or negatively correlated with YBX1 and with ESR1 in breast cancer patients. We further examined the association between YBX1-correlated genes and breast cancer outcomes in patients at Kyushu University Hospital. More than 60% of genes that are positively correlated with YBX1 are also negatively correlated with ESR1. The enhanced expression levels of the top 20 positively correlated genes mostly predict negative outcomes, while the enhanced expression levels of the top 20 negatively correlated genes mostly predict positive outcomes. Furthermore, in breast cancer patients at Kyushu University Hospital, the expression levels of YBX1 and YBX1-positively correlated genes were significantly higher and the expression levels of genes negatively correlated with YBX1 were significantly lower in patients who relapsed after their primary surgery than in those who did not relapse. The expression of YBX1 together with the expression of its positively or negatively correlated genes may help to predict outcomes as well as resistance to endocrine therapies in breast cancer patients. Determining the expression of YBX1 and its closely correlated genes will contribute to the development of precision therapeutics for breast cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26469

Publication Alerts

Research Papers:

Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer

Abstract